Orkambi® (lumacaftor/ivacaftor) – Expanded indication, new strength

- On September 2, 2022, Vertex announced the FDA approval of Orkambi (lumacaftor/ivacaftor), for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the *F508del* mutation in the *CFTR* gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the *F508del* mutation on both alleles of the *CFTR* gene.
    - Orkambi was previously approved for this indication in patients aged 2 years and older.
    - The efficacy and safety of Orkambi have not been established in patients with CF other than those homozygous for the *F508del* mutation.
- In addition to the expanded indication, a new dosage strength of the oral granules was approved (lumacaftor 75 mg/ivacaftor 94 mg unit-dose packets).
    - The oral granules were previously approved as lumacaftor 100 mg/ivacaftor 125 mg and lumacaftor 150 mg/ivacaftor 188 mg unit-dose packets.
    - Orkambi is also available as 100 mg/ivacaftor 125 mg and lumacaftor 200 mg/ivacaftor 125 mg oral tablets.
- The approval of Orkambi for the expanded was supported by evidence from adequate and well-controlled studies of Orkambi in patients 12 years of age and older with additional data as follows:
    - Extrapolation of efficacy in patients aged 12 years and older homozygous for the *F508del* mutation in the *CFTR* gene to pediatric patients aged 1 through 11 years with support from population pharmacokinetic analyses showing similar drug exposure levels in patients aged 12 years and older and in patients aged 1 through 11 years.
    - Additional safety data were obtained from a 24-week, open-label trial in 46 patients aged 1 to 2 years at screening (mean age at baseline 18.1 months). The safety profile was similar to that in patients aged 2 years and older.
- The recommended oral dosage of Orkambi in pediatric patients aged 1 through 2 years is based on age and weight (listed below). Orkambi is given every 12 hours (once in the morning and once in the evening).
    - 7 kg to < 9 kg: 1 packet of lumacaftor 75 mg/ivacaftor 94 mg granules twice daily
    - 9 kg to < 14 kg: 1 packet of lumacaftor 100 mg/ivacaftor 125 mg granules twice daily
    - ≥14 kg: 1 packet of lumacaftor 150 mg/ivacaftor 188 mg granules twice daily
- Refer to the Orkambi drug label for dosing for other pediatric and adult patients.
- Vertex's launch plans for the new oral granule dosage strength are pending.